Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Schering-Plough Products L.L.C.
483
•Schering-Plough Products L.L.C.•June 5, 2001

Schering-Plough Products L.L.C. – FDA 483, Jun 5, 2001

Record Details

During an FDA inspection from May 1 to June 5, 2001, at Schering-Plough Products L.L.C. in Las Piedras, PR, significant deviations from regulatory requirements were observed. The company failed to follow its approved manufacturing process for K-Dur Extended Release Tablets, utilizing untested sub-batches and not ensuring content uniformity. A critical absence of validation/qualification master plans was noted, alongside incomplete corrective actions from a previous inspection concerning data maintenance and security for laboratory instruments, with raw data not being retained.

The firm's Out-of-Specification (OOS) laboratory investigation system was inadequate, characterized by re-testing without justification, unsupported conclusions for invalidating original data, and insufficient corrective actions. This included invalidating numerous OOS results based on unproven causes and continued use of malfunctioning dissolution equipment. Furthermore, manufacturing processes for Theophylline tablets, Rebetol 200mg Capsules, and Normadyne tablets were unvalidated or inadequately validated, with such products still being distributed. Process changes for Bulexin lacked proper documentation or revalidation. Laboratory analytical balances did not comply with USP standards, and essential records, including justifications for dissolution guidelines, particle size specifications, and raw data for method transfers, were unavailable or destroyed. These findings necessitate comprehensive corrective and preventive actions to ensure compliance with Good Manufacturing Practices.

Company
Schering-Plough Products L.L.C.
Inspection date
June 5, 2001
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Steven Barber (District Director at FDA)
  • Arlene M. Badillo (Química en CBP)
View Company Profile

ID · 14a97110-6171-4b14-b206-bdd4e842d5ed

Violation Codes10
21 CFR 211.100(a)21 CFR 211.160(b)FD&C Act 801(a)(3)21 CFR 211.19221 CFR 211.84(d)(2)21 CFR 211.22(d)21 CFR 210.1(b)21 CFR 211.165(e)21 CFR 211.67(a)21 CFR 211.25(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Schering-Plough Products L.L.C.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.